骨质疏松症与药物.ppt

评估药物疗效的最终指标 骨密度和骨质量都只能部分的反映骨折的危险，作为评估药物疗效的指标具有局限性 所以，用骨折风险作为评估药物治疗效果的最终指标 Fosamax? (alendronate) SmPC. London, UK: EMA; 2010; 2. Fosamax? (alendronate) PI. Whitehouse Station, NJ: Merck Co Inc. 2011; 3. Black DM, et al. J Clin Endo Metab. 2000;85:4118–4124; 4. Prolia? (denosumab) SmPC. London, UK: EMA; 2011; 5. Prolia? (denosumab) PI. Thousand Oaks, CA: Amgen; 2011; 6. Bonviva? (ibandronate) SmPC. London, UK: EMA; 2011; 7. Boniva? (ibandronate) PI. South San Francisco, US: Genentech Inc.; 2011; 8. Miacalcic? (SCT nasal spray) SmPC. London, UK: EMA; 2011; 9. Miacalcin ? (SCT nasal spray) PI. E